New injection aims to shrink skin tumors before surgery

NCT ID NCT06014086

Ongoing Disease control Sponsor: Phio Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a drug called PH-762, injected directly into skin tumors, for people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Participants receive four weekly injections into one tumor, then have it surgically removed about two weeks later. The main goal is to check safety and see how the body processes the drug, while also watching for tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PH-762 (a drug that targets PD-1 to help the immune system fight cancer)
What this could lead to: If successful, this could point toward a new way to shrink skin cancers before surgery, potentially improving outcomes.
What could go wrong: This is a very early (Phase 1) trial with only 30 people, so it's mainly checking safety. It may not shrink tumors or work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA OF SKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma cutaneous neuroendocrine carcinoma melanoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA OF SKIN MERKEL CELL CARCINOMA OF SKIN SQUAMOUS CELL CARCINOMA OF THE SKIN

Contacts and locations

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Centricity Research

Columbus, Ohio, 43213, United States
Integrity Research

Delray Beach, Florida, 33445, United States
Paradigm Clinical Research

San Diego, California, 92108, United States
Skin Cancer and Dermatology Institute

Reno, Nevada, 89509, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.